November 18, 2026
Health news, explained with evidence
LIVE

FDA Approves First Factor XIa Inhibitor, Sunharbo, for Secondary Stroke Prevention

🧠 AI Analysis 2 min read 👁 6

The U.S. Food and Drug Administration has approved Sunharbo as the first factor XIa inhibitor to help prevent secondary strokes when combined with antiplatelet therapy.

FDA Approves First Factor XIa Inhibitor, Sunharbo, for Secondary Stroke Prevention🧠AI Analysis

Photo: Medical Xpress

Key points

  • FDA approved Sunharbo (asundexian) 50 mg for secondary stroke prevention.
  • Phase 3 OCEANIC-STROKE study showed a 26% reduction in ischemic stroke risk.
  • The therapy carries increased bleeding risks for patients over 75 and during early treatment.

The U.S. Food and Drug Administration (FDA) has granted approval to Sunharbo 50 mg tablets (asundexian) for use alongside antiplatelet therapy to lower stroke risks in adults who have experienced a recent mild-to-moderate noncardioembolic ischemic stroke or a high-risk transient ischemic attack (TIA). This regulatory decision marks the introduction of the first factor XIa inhibitor approved for this specific clinical application.

Regulatory authorization stems from the phase 3 OCEANIC-STROKE trial, which evaluated 12,327 adult participants. Individuals were randomized to receive either Sunharbo or a placebo within 72 hours of symptom onset. Findings indicate that a once-daily 50 mg dose of Sunharbo, paired with antiplatelet medication, reduced ischemic stroke risk by 26% compared to the placebo group over a median treatment duration of 14.2 months.

While overall major bleeding rates remained comparable between the cohorts, researchers noted an increased bleeding risk among patients over the age of 75 and throughout the initial 90 days of treatment. Gastrointestinal bleeding was more frequent in the medication group, and diarrhea emerged as the most common adverse reaction, affecting 3% or more of treated patients. Additionally, the therapy is not recommended for individuals with moderate or severe hepatic impairment, those taking strong CYP3A4 and P-gp inducers, or patients with atrial fibrillation.

What to know: Sunharbo is a new prescription option for secondary stroke prevention in specific adult populations, but it carries notable bleeding risks in certain demographic groups. Always consult a qualified healthcare provider for personalized medical decisions and treatment strategies.

Source Medical Xpress — medicalxpress.com/news/2026-11-fda-factor-xia-inhibitor-secondary.html ↗

Contact the newsroom

Got a tip, a proposal or a partnership question? Write to us and we will reply shortly.